“Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults.”, J Infect Dis, vol. 197, no. 5, pp. 667-75, 2008.
, “Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.”, J Infect Dis, vol. 198, no. 5, pp. 635-41, 2008.
, “Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial.”, J Infect Dis, vol. 198, no. 9, pp. 1309-16, 2008.
, “Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure.”, Clin Vaccine Immunol, vol. 16, no. 4, pp. 558-66, 2009.
, “Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults.”, Vaccine, vol. 27, no. 37, pp. 5091-5, 2009.
, “Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults.”, Vaccine, vol. 28, no. 38, pp. 6367-73, 2010.
, “Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.”, Vaccine, vol. 29, no. 34, pp. 5666-74, 2011.
, “Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant.”, J Infect Dis, vol. 203, no. 5, pp. 666-73, 2011.
, “Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes.”, J Infect Dis, vol. 206, no. 7, pp. 1069-77, 2012.
, “Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons.”, J Infect Dis, vol. 206, no. 6, pp. 811-20, 2012.
, “Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.”, J Infect Dis, vol. 206, no. 6, pp. 828-37, 2012.
, “Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.”, J Infect Dis, vol. 207, no. 12, pp. 1888-97, 2013.
, “Assessment of safety in newborns of mothers participating in clinical trials of vaccines administered during pregnancy.”, Clin Infect Dis, vol. 59 Suppl 7, pp. S415-27, 2014.
, “Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children.”, Pediatr Infect Dis J, vol. 33, no. 8, pp. 865-71, 2014.
, “Determination of the 50% human infectious dose for Norwalk virus.”, J Infect Dis, vol. 209, no. 7, pp. 1016-22, 2014.
, “Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults.”, Vaccine, vol. 32, no. 47, pp. 6284-93, 2014.
, “Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.”, JAMA, vol. 312, no. 14, pp. 1420-8, 2014.
, “Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals.”, Vaccine, vol. 32, no. 23, pp. 2732-9, 2014.
, “Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.”, JAMA, vol. 312, no. 14, pp. 1409-19, 2014.
, “Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects.”, Vaccine, vol. 33, no. 39, pp. 5225-34, 2015.
, “Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.”, JAMA, vol. 314, no. 3, pp. 237-46, 2015.
, “Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.”, Vaccine, vol. 33, no. 1, pp. 163-73, 2015.
, “Safety and Immunogenicity of Full-Dose Trivalent Inactivated Influenza Vaccine (TIV) Compared With Half-Dose TIV Administered to Children 6 Through 35 Months of Age.”, J Pediatric Infect Dis Soc, vol. 4, no. 3, pp. 214-24, 2015.
, “Cell mediated immune responses following revaccination with an influenza A/H5N1 vaccine.”, Vaccine, vol. 34, no. 4, pp. 547-554, 2016.
, “Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases the Duration of T cell Responses Induced by a Heterologous H5 Booster Vaccination.”, J Infect Dis, vol. 214, no. 7, pp. 1020-9, 2016.
,